Defining high-risk patients: beyond the 8the AJCC melanoma staging system.

Autor: Broseghini E; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, 40126, Italy., Veronesi G; Department of Medical and Surgical Science (DIMEC), University of Bologna, Bologna, 40138, Italy.; Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, 40138, Italy., Gardini A; Department of Statistical Sciences, University of Bologna, Bologna, 40126, Italy., Venturi F; Department of Medical and Surgical Science (DIMEC), University of Bologna, Bologna, 40138, Italy. federico.venturi@hotmail.it.; Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, 40138, Italy. federico.venturi@hotmail.it., Scotti B; Department of Medical and Surgical Science (DIMEC), University of Bologna, Bologna, 40138, Italy.; Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, 40138, Italy., Vespi L; Department of Medical and Surgical Science (DIMEC), University of Bologna, Bologna, 40138, Italy.; Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, 40138, Italy., Marchese PV; Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, 40138, Italy., Melotti B; Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, 40138, Italy., Comito F; Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, 40138, Italy., Corti B; Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, 40138, Italy., Ferracin M; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, 40126, Italy.; Department of Medical and Surgical Science (DIMEC), University of Bologna, Bologna, 40138, Italy., Dika E; Department of Medical and Surgical Science (DIMEC), University of Bologna, Bologna, 40138, Italy.; Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, 40138, Italy.
Jazyk: angličtina
Zdroj: Archives of dermatological research [Arch Dermatol Res] 2024 Dec 06; Vol. 317 (1), pp. 78. Date of Electronic Publication: 2024 Dec 06.
DOI: 10.1007/s00403-024-03627-4
Abstrakt: Since melanoma incidence is steadily increasing, guidelines regarding the diagnosis, staging, and treatment of melanoma are constantly being updated. In particular, the use of adjuvant therapy in stage IIb/c melanoma has been recently approved by the international regulatory agenicies. We performed a retrospective study with 92 melanoma patients namely 42 patients with IIb/c melanoma and 42 patients with IIIa stage melanoma, describing demographics, clinical, histology and disease course during the 5-year follow-up.Several significant evidences emerged between the two groups. Stage IIb/c patients possess a higher age of disease onset (69.6 vs. 55.5 years) with respect to stage III patients and the acral localization appeared as the most frequent (24% vs. 4%). Histologically, stage IIb/c melanomas more frequently exhibit ulceration (70% vs. 2%), angiotropism (54% vs. 8%) and are characterized by a greater presence of TILS (52% vs. 15%). Although it is not statistically significant, we observed a difference in terms of presence of metastasis during the 5-year follow-up: 15% of stage IIb/c patients showed metastasis vs. 4% of stage IIIa patients. Our data support the use of adiuvant immunotherapy in stage IIb/c patients.
Competing Interests: Declarations. Competing interests: The authors declare no competing interests.
(© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: